WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 597120

CAS#: 8058-79-5

Description: Paraprost consists of 1-glutamic acid, alanine & glycine; used in prostate hypertrophy drug therapy.

Chemical Structure

CAS# 8058-79-5

Theoretical Analysis

MedKoo Cat#: 597120
Name: Paraprost
CAS#: 8058-79-5
Chemical Formula: C10H21N3O8
Exact Mass: 0.00
Molecular Weight: 311.290
Elemental Analysis: C, 38.58; H, 6.80; N, 13.50; O, 41.12

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Synonym: Paraprost;

IUPAC/Chemical Name: L-alanine compound with L-glutamic acid and glycine (1:1:1)


InChi Code: InChI=1S/C5H9NO4.C3H7NO2.C2H5NO2/c6-3(5(9)10)1-2-4(7)8;1-2(4)3(5)6;3-1-2(4)5/h3H,1-2,6H2,(H,7,8)(H,9,10);2H,4H2,1H3,(H,5,6);1,3H2,(H,4,5)/t3-;2-;/m00./s1

SMILES Code: N[C@@H](CCC(O)=O)C(O)=O.N[C@@H](C)C(O)=O.NCC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 311.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Wilt TJ, Macdonald R, Ishani A, Rutks I, Stark G. WITHDRAWN: Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2011 May 11;(5):CD001042. doi: 10.1002/14651858.CD001042.pub2. Review. PubMed PMID: 21563128.

2: Okada H. [BPH pharmacotherapy (miscellaneous)]. Nihon Rinsho. 2002 Dec;60 Suppl 11:367-72. Review. Japanese. PubMed PMID: 12599602.

3: Wilt T, Mac Donald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001042. Review. Update in: Cochrane Database Syst Rev. 2011;(5):CD001042. PubMed PMID: 10796739.

4: MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000 May;85(7):836-41. Review. PubMed PMID: 10792162.

5: Mahoney JE. Plant extracts in the medical management of benign prostatic hyperplasia: fact or fiction? Can J Urol. 1995 May;2(2):125-9. PubMed PMID: 12803719.

6: Kumamoto Y, Tsukamoto T, Yachiku S, Kaneko S, Koyanagi T, Togashi M, Maru A, Tsuchida S, Nishizawa O, Orikasa S, et al. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy]. Hinyokika Kiyo. 1990 Oct;36(10):1213-32. Japanese. PubMed PMID: 1702262.

7: Maekawa M, Kishimoto T, Yasumoto R, Wada S, Harada T, Ohara T, Okajima E, Hirao Y, Ohzono S, Shimada K, et al. [Clinical evaluation of Cernilton on benign prostatic hypertrophy--a multiple center double-blind study with Paraprost]. Hinyokika Kiyo. 1990 Apr;36(4):495-516. Japanese. PubMed PMID: 1696065.

8: Yamaguchi O, Shiraiwa Y, Kobayashi M, Yokota T, Ohinata M, Aoki H, Tsuzuki T, Ohori M. Clinical evaluation of effects of prazosin in patients with benign prostatic obstruction. A double-blind, multi-institutional, Paraprost-controlled study. Urol Int. 1990;45 Suppl 1:40-6. PubMed PMID: 1690481.

9: Aito K, Watsubo E. [The conservative treatment of prostatic hypertrophy with Paraprost]. Hinyokika Kiyo. 1972 Jan;18(1):41-4. Japanese. PubMed PMID: 4112552.